June 22, 2025
at
12:00 am
EST
MIN READ
Bitcoin treasury company, Semler Scientific, recently announced their plans to acquire significantly more Bitcoin in the coming years, after the appointment of Bitcoin bull, Joe Burnett, as their Director of Bitcoin Strategy. Semler Scientific is targeting a total holding of 10,000 BTC by the end of the year, 42,000 by the end of 2026 and 105,000 by the end of 2027. At the moment, they hold 3,975 BTC, or $481.6M worth.
Semler Scientific adopted a Bitcoin treasury strategy in mid 2024, following in the footsteps of Michael Saylor’s Strategy (then, MicroStrategy). Their publicly traded stock, SMLR, has since risen approximately 50% from their first announcement, with the recent news pushing their stock up 13.15%.
Semler Scientific's pivot is noteworthy because of its original line of business. Its core operations - manufacturing products for chronic diseases - are entirely unrelated to the world of finance or digital assets. This shift to a dual strategy of continuing its healthcare mission while also aggressively accumulating $BTC
is unusual. It signals a belief that the long-term value creation for shareholders from holding a hard asset like Bitcoin could potentially eclipse the returns generated from its legacy business alone.
Hiring a Director of Bitcoin Strategy, and a known Bitcoin bull, transforms the Bitcoin strategy from a passive balance sheet item into an active, core component of the company's identity and future, requiring specialised expertise to navigate the volatile market and complex operational security.
The significant rise in Semler's stock price (SMLR) reflects a well-documented market phenomenon. When a public company commits to a Bitcoin treasury strategy, its stock often begins to trade as a proxy for $BTC
itself, attracting a new class of investors. This can lead to the stock trading at a premium, often referred to as the "Saylor Premium" after MicroStrategy's success. Shareholders are showing confidence that the potential upside of holding $BTC
on the balance sheet outweighs the perceived risks of such an unconventional corporate treasury strategy.